Deep Dive Sessions
MedTech Bridge has monthly sessions that dive into different topics all relevant for securing successful US market entry. For Ilkka Juuso, Co-Founder and COO at the next-generation brain monitoring company Cerenion, it is exactly these sessions and the connections made that have enhanced his confidence in a US market entry. Here is his experience:
Dr. Ilkka Juuso,
Co-Founder and COO,
Why did you decide to join the program?
I heard about the program through a colleague and immediately thought that the idea of Nordic startups somehow joining forces, under the umbrella of the MTB, and figuring out the best way to cross the Atlantic together was both an intriguing prospect and just the right sort of an aspirational goal. I was hooked right away. In general, too, I always look for opportunities to share and to learn, so this program had instant appeal for me. Luckily, we got in.
What were your initial expectations when joining the program?
We came to this with an open mind expecting to meet mentors, peers, and potential customers, and to learn what qualities and knowledge we had to pack for the voyage, if you will. We thought that we knew how to make our company a success in Europe, but we wanted to figure out what adjustment was needed to make a proper splash on the other side of the big pond. I was expecting to learn a lot on, for example, regulations, reimbursement, and the market environment in general – from both the theoretical and the practical sides. The program delivered on all fronts.
What is your overall experience with MedTech Bridge?
The one singular part of the program that has impressed me the most has been the sessions organized around key topics. These sessions brought in subject matter experts who clearly wanted to bring the cohort members the best knowledge in the most accessible form, and were not afraid to take questions either. And the members could chime in with their experiences too. The same topics are perhaps covered on many other forums, at least in name, but I can honestly say that rarely, if ever, as effectively as by the MTB. I learned a lot from the presentations given as part of these sessions, but the real opportunity for me was being able to ask further questions and even have one-on-one meetings with the experts.
The sessions no doubt grew out of a genuine wish to support the cohort companies and find ways to both expand their understanding of key matters and fuel them forward. This was evident sitting in the audience, but it takes a dedicated staff and willingness to both listen and to act in order to bring all this about. The on-demand help and the doors the program organizers opened for us are nothing short of spectacular. So, I would say that as impressive as the sessions were, the friendly and helpful attitude of the well-connected MTB staff was the secret sauce. I can only recommend the program unreservedly.
How has your experience with MedTech Bridge prepared you for the future?
The connections made and the lessons learned have greatly enhanced our chances of success as we navigate the waters going forward. The knowledge we have gained will no doubt be built on over the coming years, but the foundations have now been laid – or maybe the keel of the ship, to use a nautical reference. MTB has given us just the right sort of help to find answers and connections to feel certain in our course and position. I only hope the pandemic will subside and we will get to both meet up in Denmark and also step over to the US in one way or another with the MTB.
Cerenion provides AI tools for the analysis of brain function in intensive care. Patented Cerenion® C-Trend® technology reveals the status of the brain as a simple index - at the bedside and without requiring any changes to the care of the patient. The solution combines standard EEG measurement with clinically proven artificial intelligence to allow medical professionals to see how their patient's brain is doing. The index works with both short-term EEG and continuous EEG, where it offers experts a powerful view over long-term measurements.
The technology has the potential of improving both the quality and the cost of intensive care.